Literature DB >> 26509743

Minimizing metastatic risk in radiotherapy fractionation schedules.

Hamidreza Badri1, Jagdish Ramakrishnan, Kevin Leder.   

Abstract

Metastasis is the process by which cells from a primary tumor disperse and form new tumors at distant anatomical locations. The treatment and prevention of metastatic cancer remains an extremely challenging problem. This work introduces a novel biologically motivated objective function to the radiation optimization community that takes into account metastatic risk instead of the status of the primary tumor. In this work, we consider the problem of developing fractionated irradiation schedules that minimize production of metastatic cancer cells while keeping normal tissue damage below an acceptable level. A dynamic programming framework is utilized to determine the optimal fractionation scheme. We evaluated our approach on a breast cancer case using the heart and the lung as organs-at-risk (OAR). For small tumor [Formula: see text] values, hypo-fractionated schedules were optimal, which is consistent with standard models. However, for relatively larger [Formula: see text] values, we found the type of schedule depended on various parameters such as the time when metastatic risk was evaluated, the [Formula: see text] values of the OARs, and the normal tissue sparing factors. Interestingly, in contrast to standard models, hypo-fractionated and semi-hypo-fractionated schedules (large initial doses with doses tapering off with time) were suggested even with large tumor α/β values. Numerical results indicate the potential for significant reduction in metastatic risk.

Entities:  

Mesh:

Year:  2015        PMID: 26509743     DOI: 10.1088/0031-9155/60/22/N405

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  1 in total

Review 1.  Optimal treatment and stochastic modeling of heterogeneous tumors.

Authors:  Hamidreza Badri; Kevin Leder
Journal:  Biol Direct       Date:  2016-08-23       Impact factor: 4.540

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.